ClinicalTrials.gg

Program

HDM1005

A development code. Also written as “HDM1005 1”, “HDM1005 2” and “HDM1005 dose level 1”.

Its studies are mostly in Obesity · Diabetes Mellitus, Type 2 · Sleep Apnea, Obstructive · Overweight, led by Huadong Medicine.

Furthest: phase 3, since Nov 17, 202510 company-led studies, 10 open or runningNext primary completion: Dec 1, 2026 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Huadong Medicine1010 open or runningphase 3since Nov 17, 2025Jul 25, 2025Dec 1, 2026phase 1 · NCT07502001

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 25, 2025First study: phase 2 study in Diabetes Mellitus, Type 2First studyNCT07109700 · 216 planned · China
  2. Nov 17, 2025Phase 3 study in ObesityPhase 3 reachedNCT07279194 · 825 planned · China
  3. Feb 2, 20262 phase 3 studies in Diabetes Mellitus, Type 2NCT07394114, NCT07417306
  4. Mar 19, 2026Phase 1 study in OverweightNCT07502001 · 42 planned · China
  5. Mar 31, 2026Phase 2 study in ObesityNCT07521631 · 372 planned · China
  6. Apr 23, 2026Phase 1 study in OverweightNCT07559240 · 30 planned · China
  7. Aug 24, 20262 phase 3 studies in Sleep Apnea, ObstructiveNCT07787260, NCT07794397
  8. Sep 14, 2026Phase 1 study in Overweight and/or ObesityNCT07828197 · 135 enrolled · China

Ahead

  1. Dec 1, 2026Primary completion: phase 1 study in OverweightNCT07502001
  2. Feb 4, 2027Primary completion: phase 2 study in ObesityNCT07521631
  3. Aug 28, 2027Primary completion: phase 3 study in Diabetes Mellitus, Type 2NCT07394114
  4. Aug 30, 2027Primary completion: phase 3 study in Diabetes Mellitus, Type 2NCT07417306

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 10 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07828197Overweight and/or Obesity · China1Active, not recruitingOct 2026135
NCT07794397Sleep Apnea, Obstructive · China3Not yet recruitingSep 2028200
NCT07787260Sleep Apnea, Obstructive · China3Not yet recruitingMar 2028200
NCT07559240Overweight · China1Not yet recruitingJun 12, 202630
NCT07521631Obesity · China2RecruitingFeb 4, 2027372
NCT07502001Overweight · China1Not yet recruitingDec 1, 202642
NCT07417306Diabetes Mellitus, Type 2 · China3Not yet recruitingAug 30, 2027912
NCT07394114Diabetes Mellitus, Type 2 · China3RecruitingAug 28, 2027240
NCT07279194Obesity · China3RecruitingSep 20, 2026825
NCT07109700Diabetes Mellitus, Type 2 · China2RecruitingJan 31, 2026216

How it is read

Names in the registry

  • “HDM1005”, 4 entries
  • “HDM1005 1”, 4 entries
  • “HDM1005 2”, 4 entries
  • “HDM1005 dose level 1”, 1 entry
  • “HDM1005 dose level 2”, 1 entry

Codes read as this program: HDM1005.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.